{"prompt": "['Worsening of signs and symptoms of the malignancy under study. Disease progression assessed by', 'measurement of malignant lesions on radiographs or other methods should not be reported as an', 'adverse event, unless the outcome is fatal during the study or within the safety reporting period (up', 'to 28 days after the 24th cycle) - see definition of serious adverse event below.', 'Signs or symptoms resulting from exercise overload', 'Drug interactions', 'For laboratory abnormalities, the criteria for determining whether an abnormal test finding should be reported', 'as an adverse event are as follows:', 'Test result is associated with accompanying symptoms, and/or', 'Test result requires additional diagnostic testing or medical/surgical intervention, and/or', 'Test result leads to a change in study dosing outside of protocol-stipulated dose adjustments or', 'discontinuation from study, significant additional concomitant treatment, or other therapy, and/or', 'Test result is considered to be an adverse event by the Investigator', '13.1.2 Serious Adverse Events (SAE)', 'A serious adverse event (SAE) is any adverse event occurring at any level of intervention that results in any of', 'the following outcomes:', 'Results in death. If the malignancy under study has a fatal outcome during the study or within the safety', 'reporting period, the event leading to death should be reported as a Grade 5 SAE; death is an outcome', 'and not the adverse event in itself.', 'Is life-threatening (i.e., immediate risk of death from the reaction as it occurred). It does not include', 'a reaction which hypothetically might have caused death had it occurred in a more severe form.', 'Requires or prolongs inpatient hospitalisation (i.e., the event required at least a 24-hour hospitalisation or', 'prolonged a hospitalisation beyond the expected length of stay). Hospitalisation admissions and/or', 'surgical operations scheduled to occur during the study period, but planned prior to study entry are not', 'considered SAEs if the illness or disease existed before the person was enrolled in the trial, provided that', 'it did not deteriorate in an unexpected manner during the trial (e.g., surgery performed earlier)', 'Results in persistent or significant disability/incapacity. Disability is defined as a substantial', \"disruption of a person's ability to conduct normal life functions\", 'Results in a congenital anomaly or birth defect', 'Is an important medical event when, based upon appropriate medical judgment, it may jeopardise the', 'participant and require medical or surgical intervention to prevent one of the outcomes listed above.', 'Events not considered to be SAEs are hospitalisations for:', 'Routine treatment or monitoring of the studied indication, not associated with deterioration in condition', 'Elective or pre-planned treatment for a pre-existing condition that did not worsen', 'Emergency outpatient treatment for an event not fulfilling the serious criteria outlined above and not', 'resulting in inpatient admission', 'Respite care or social admissions', '13.1.3 Non-Serious Adverse Events', 'All other events.', '13.2 Expectedness', 'INTERVAL Protocol Version 4.0, 19 April 2018', '47']['An adverse event or suspected adverse reaction is considered \"unexpected\" if it is not listed above or included', 'in the following list:', 'Bone pain, pathological skeletal fracture', 'Musculoskeletal injury (sprain, strain)', 'Joint pain', 'Falls', 'Muscle soreness', '13.3 Attribution', 'A suspected adverse reaction means any adverse event for which there is reasonable possibility that the', 'intervention caused the adverse event. For the purposes of safety reporting, \"reasonable possibility\" means', 'there is evidence to suggest a causal relationship between the intervention and the adverse event.', 'The Investigator will assign attribution of the possible association of the event with the study intervention using', 'the following definitions:', 'Unrelated to the exercise intervention: The adverse event is Unlikely or Not Related to the exercise', 'intervention', 'Related to exercise intervention: The adverse event is Possibly, Probably, or Definitely related to the exercise', 'intervention.', '13.4 Severity', 'Signs or symptoms should be graded and recorded by the Investigator according to the National Cancer', \"Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 (SOM: Appendix 30). When\", 'specific adverse events are not listed in the CTCAE, they are to be graded as mild, moderate, severe, or life-', 'threatening according to the following grades and definitions:', 'Table 6. AE Severity Grading', 'Severity', '(Toxicity Grade)', 'Description', 'Grade 1', 'Mild; asymptomatic or mild symptoms; clinical or diagnostic', 'observations only; intervention not indicated', 'Grade 2', 'Moderate; minimal, local or non-invasive intervention indicated;', 'limiting age- appropriate instrumental activities of daily living (ADL)', 'Severe or medically significant but not immediately life-threatening;', 'hospitalisation or prolongation of hospitalisation indicated; disabling;', 'Grade 3', 'limiting self-care ADL', 'Grade 4', 'Life-threatening consequences; urgent intervention indicated', 'Grade 5', 'Death related to AE', '13.5 Reporting Requirements', 'All AEs and SAEs whether reported by the patient, discovered during questioning, directly observed, or detected', \"by physical examination, laboratory test or other means must be recorded in the patient's medical record and on\", 'the AE form in the online study database. All AEs should be reviewed by the site PI. The Investigator is', 'responsible for notifying the Institutional Review Board/Independent Ethics Committee (IRB/IEC) about AEs in', 'accordance with local regulations.', '13.5.1 SAE Reporting', 'INTERVAL Protocol Version 4.0, 19 April 2018', '48']\n\n###\n\n", "completion": "END"}